Vernalis hit by fresh U.S. setback for cough and cold drug

LONDON (Reuters) - Shares in Vernalis fell 5.3 percent on Monday as the British biotech company backed by fund manager Neil Woodford and his previous employer Invesco announced a fresh setback for a key new drug in the United States.